>
COMMANDS Global: GP Symbol: IBM FA
↑↓ Navigate Enter Open Esc Close ` Toggle

Summary

10.90 -0.03 (-0.27%) 10/02/2026
Corvus Pharmaceuticals, Inc. (CRVS)
Performance
Historical returns
1D
-0.27%
1W
-8.17%
1M
-23.24%
3M
-28.43%
6M
-25.80%
1Y
54.83%
5Y
127.08%
Snapshot
Key statistics
Close
10.90
Change
-0.03
Change %
-0.27%
Open
11.11
Day Range
10.64 – 11.11
Volume
1,354,125
Avg Vol (20d)
1,253,671
Rel Vol
1.08x
52W Range
6.39 - 26.95
vs 52W High
-59.55%
vs 52W Low
70.58%
Gap
-0.61
Market Cap
USD 916.59M
Beta
0.64
Price Chart
Advanced chartCompare
Last 730 data points are shown. To view all data, Create a free account
Bull vs Bear
2 bullish · 7 bearish points
Bullish view
  • Has recovered 67.7% off the 52-week low of $6.50.
  • Sits 204.3% below the average analyst target of $33.17 across 6 firms.
Bearish view
  • Trades 23.0% below its 200-day average, a downtrend still intact.
  • Still 57.3% below its 52-week high of $25.52.
  • Lagged the S&P 500 by 30.6% over the last quarter (-28.1% against +2.4%).
  • Trades at 82.3× the 2030 consensus EPS of $0.13, a multiple that leaves little room for disappointment.
  • Missed consensus EPS in 4 of the last 8 quarters.
  • The Q2 '26 quarter missed on EPS by $0.03 (19.4% below consensus).
  • FY2025 earnings fell 75.5% to -$15.28M.
Both sides are generated from reported financials, consensus estimates, analyst targets and the price series — not from opinion.
Notable Price Movement
Historical returns
Oct 2
2026
$10.90 0.27%Latest
Corvus Pharmaceuticals fell 0.27% to $10.90. Shares opened with a 1.65% gap up and reversed through the session and marked a 4th consecutive decline. The move left the stock 57.3% below its 52-week high.
Sep 24
2026
$11.80 5.90%
Corvus Pharmaceuticals fell 5.90% to $11.80, a 1.8σ move against its 60-day volatility. This was largely stock-specific: the S&P 500 fell 0.08% while Healthcare peers (XLV) rose 0.63% that session, leaving about 5.8 points of the move unexplained by the market after adjusting for a 0.64 beta.
Sep 23
2026
$12.54 6.70%
Corvus Pharmaceuticals fell 6.70% to $12.54, its biggest one-day drop in 1 month and a 2.1σ move against its 60-day volatility. This was largely stock-specific: the S&P 500 fell 0.72% while Healthcare peers (XLV) fell 0.64% that session, leaving about 6.1 points of the move unexplained by its sector. Shares opened with a 1.04% gap down.
Sep 22
2026
$13.44 8.21%
Corvus Pharmaceuticals rose 8.21% to $13.44, its biggest one-day gain in 5 months and a 2.7σ move against its 60-day volatility. This was largely stock-specific: the S&P 500 fell 0.02% while Healthcare peers (XLV) rose 0.52% that session, leaving about 7.7 points of the move unexplained by its sector. Shares opened with a 1.05% gap up and closed near the session high (98% of the day's range). Historically, after 2.5σ-or-larger up days, Corvus Pharmaceuticals returned +11.78% on average over the following 5 sessions (50% positive, n=14).
Sep 16
2026
$12.23 5.56%
Corvus Pharmaceuticals fell 5.56% to $12.23, its biggest one-day drop in 4 weeks and a 1.8σ move against its 60-day volatility. This was largely stock-specific: the S&P 500 fell 0.44% while Healthcare peers (XLV) rose 0.07% that session, leaving about 5.3 points of the move unexplained by the market after adjusting for a 0.64 beta. Shares closed near the session low (5% of the day's range).
Sep 9
2026
$13.33 4.31%
Corvus Pharmaceuticals fell 4.31% to $13.33, its biggest one-day drop in 3 weeks, on 1.5× average volume. This was largely stock-specific: the S&P 500 fell 0.46% while Healthcare peers (XLV) fell 0.33% that session, leaving about 4.0 points of the move unexplained by its sector. Shares lost their 200-day moving average and marked a 3rd consecutive decline.
Computed from adjusted closes over the last 22 sessions; attribution vs SPY and XLV.
Price Performance
All periods
PeriodPeriod LowPeriod HighPerformance
1-Month10.64 +2.44%
on 10/02/26
Open 14.20
14.82 -26.45%
on 09/02/26
-3.30 (-23.24%)
since 09/02/26
3-Month10.64 +2.44%
on 10/02/26
Open 15.17
16.47 -33.82%
on 07/09/26
-4.27 (-28.15%)
since 07/06/26
6-Month10.64 +2.44%
on 10/02/26
Open 14.69
19.70 -44.67%
on 04/22/26
-3.79 (-25.80%)
since 04/02/26
YTD6.39 +70.58%
on 01/12/26
Open 7.32
26.95 -59.55%
on 01/23/26
+3.58 (+48.91%)
since 01/02/26
52-Week6.39 +70.58%
on 10/08/25
Open 7.26
26.95 -59.55%
on 01/23/26
+3.64 (+50.14%)
since 10/01/25
5-Year0.61 +1,695.72%
on 03/28/23
Open 6.80
26.95 -59.55%
on 01/23/26
+4.10 (+60.29%)
since 09/24/21
New Highs
Historical highs
5-Day
0×
-8.17% from peak
1-Month
0×
-25.60% from peak
3-Month
2×
-32.72% from peak
6-Month
5×
-38.94% from peak
YTD
4×
-57.29% from peak
52-Week
14×
-57.29% from peak
2-Year
18×
-57.29% from peak
3-Year
43×
-57.29% from peak
5-Year
11×
-57.29% from peak
10-Year
18×
-57.29% from peak
Financial SnapshotFY 2025
Full financials
Revenue
n/a
Net Income
-USD 15.28M
-75.5% YoY
EPS
-0.19
-81.4% YoY
Gross Margin
n/a
Operating Margin
n/a
Net Margin
n/a
EBITDA
-USD 15.18M
Free Cash Flow
-USD 32.97M
ROE
-25.0%
ROA
-21.5%
Debt / Equity
0.02x
net debt -USD 3.64M
Cash & Equiv.
USD 4.58M
News
All news
10/01 06:01 ET · defenseworld.net
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up – Still a Buy?
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS - Get Free Report)'s stock price gapped up before the market opened on Tuesday. The stock had previously closed at $11.87, but opened at $12.37. Corvus Pharmaceuticals shares last traded at $11.8020, with a volume of 159,690 shares changing hands. Wall...
09/30 16:05 ET · globenewswire.com
Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for the treatment of patients with hidradenitis...
09/03 08:30 ET · globenewswire.com
Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat...
08/27 07:30 ET · globenewswire.com
Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthma  Data in T cell lymphoma demonstrated anti-tumor activity based on tumor intrinsic and tumor extrinsic effects on microenvironment Highlights...
08/07 04:44 ET · seekingalpha.com
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript
08/06 20:04 ET · marketbeat.com
Corvus Pharmaceuticals Q2 Earnings Call Highlights
Corvus Pharmaceuticals NASDAQ: CRVS reported a wider second-quarter loss as it increased spending on clinical development of soquelitinib, its selective ITK inhibitor, while outlining expected milestones across programs in peripheral T-cell lymphoma, atopic dermatitis, hidradenitis suppurativa and...
08/06 16:01 ET · globenewswire.com
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results
Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track Soquelitinib's potential in atopic dermatitis and broader immunology and inflammation indications supported by Phase 1 clinical, immunologic and...
07/30 16:01 ET · globenewswire.com
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

Market News ×
Loading news…